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Product (material) patents were introduced to Japan in 1976.  We examine data prior to 
1976 and years immediately following to determine the law’s effect on domestic 
pharmaceutical market, innovation by pharmaceutical firms, and relationship of the 
Japanese market to the rest of the world.  There is evidence that the domestic market 
became more concentrated and quality of pharmaceutical innovation changed after the 
introduction. This is because introduction of product patents is different from simple 
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We identify possible consequences of the introduction of the product patents in Japan in 
1976.  We look at changes that occurred in the domestic pharmaceutical market, 
innovation and changes in the context of the international pharmaceutical market.  
 
At the time it was envisaged that stronger patent protection, such as product (material) 
patents, would make some substitutes unavailable to the market and result in higher price 
of products that are protected by patents.  In case of Japan, prescription drug prices are 
set by the Ministry of Health, Labor and Welfare for the purpose of insurance 
reimbursement and not determined by the market.  The availability of products was not 
adversely affected by the stronger patents.   This was the case for over the counter (OTC) 
products as well, of which prices have been falling.  We actually observe a steady 
increase in number of drug products after the introduction.   We suspect there was a mild 
reorganization of pharmaceutical market.  Changes in concentrations ratios suggest that 
the very largest firms became more dominant while some large firms either left the 
market or lost shares.  Since the total number of pharmaceutical firms did not decline, the 
most dominant products seem to have increased market share.  Stronger protection 
increased foreign investment in production and research facilities in Japan. 
 
Both the absolute number of R&D expenditure and as proportion of sales increased 
around 1976 and continued to increase.  Firms also increased the proportion of research 
employees.  Foreign firms also became innovative by building research facilities in Japan 
after the law change.  Although we do not observe significant increase in number of 
patents, there was significant reduction in use of process patents, meaning firms did in 
deed take advantage of product patents.  At the same time there was a significant increase 
in original drugs developed in Japan and a change in trading pattern of pharmaceutical 
technologies.  These facts lead us to conclude that quality of Japanese pharmaceutical 
innovation shifted (such as from modification to application (Hara, 2002), or from 
process modification to product modification) after the introduction. The quality became 
more in line with the imported technologies suggesting Japan “caught up”.  
 
In considering product patents, public health policy and industrial policy should be 
separated.  In case of Japan, product patents were introduced from industrial policy point 
of view.  Governments control price of drugs and delivery of health services to counter 
patent protection.  The long run benefits from introduction of patents take longer to 
materialize.  But such benefits may increase the national resources available for public 




The most significant change for the Japanese pharmaceutical industry in terms of 
intellectual property regime was the introduction of product patents in 1976.  This was 
followed in 1988 with extension of protection length and relaxation of the description 
requirements for patent specifications in 1994.   
 
The object of this paper is to identify the consequences of the introduction of product 
patents to the pharmaceutical industry.  We will first examine its effect on the domestic 
market, prices, product availability and concentration of firms.  One expects the most 
direct effect of intellectual property will be to innovation. Level of innovation may not be 
the only measure of change in innovation behavior from change (Sakakibara and 
Branstetter, 2001).   We focus on the heterogeneous nature of pharmaceutical innovation 
(Hara, 2003).  We will look at how R&D behavior, patenting and product introduction 
was affected in addition to the traditional measurements such as R&D expenditure and 
number of patents.  Finally we will examine how the change in domestic law affected 
Japanese firms in the international pharmaceutical market context. 
 
We note that establishment of the National Health Insurance System (NHI) in 1961 
which included reimbursement of drugs increased profitability of the pharmaceutical 
industry significantly.  The liberalization of capital investment in 1975 meant that foreign 
firms were now able to produce and market directly in Japan and no longer needed to rely 
on Japanese firms to produce under license.  There were also two important changes in 
the Japanese patent system in 1970.  The automatic early publication of patent 
applications and examination request system were introduced.  After 1970, patent 
applications, independent of if it becomes a registered patent or not, are published 




Since the Japanese patent system was established in 1985, modeled after the French 
system, chemical materials including pharmaceuticals were not patentable.  This 
remained the case through several major changes (in years 1999, 1899, 1909 and 1921). 
Introduction of product patents was considered in 1970 but the state of innovation in 
Japan was judged not to have reached the level to benefit from such change.  Only the 
early publication of applications and the examination request system were introduced. 
 
Initially, process patents were considered effective in promoting introduction of products 
with more efficient production, lowering costs and promoting competition.  If a 
patentable inventive step were easier to achieve with process innovation than with 
product innovation, restricting patents to process also means greater number of firms 
producing, promoting production efficiency.   However soon it became evident that 
opportunities for process innovation of a given drug were being exhausted.  This resulted 
in increase in patent infringement suits as new “innovations” became less innovative and 
similar to existing ones.  But the firms continued to pour resources into finding new process methods rather than finding new drugs.  The whole innovation system at all 
levels of research and development were devoted to finding new processes.   It seemed 
that protection of the new drug itself was necessary to change the direction on innovation, 
not only at the application and development levels but to promote greater basic research.   
 
In 1970, Japan Patent Association asked its 335 member firms their view on chemical 
product patents and pharmaceutical patents (Table 1).   The proportion of those in favor 
of making new chemical materials was 59.6% and the proportion for pharmaceutical 
patents was only 38.2%.  The high proportion of “No Opinion” could just be because the 
effect of pharmaceutical patents will be industry specific and reflects indifference of 
other industries.    The survey numbers did not suggest an overwhelming support but the 
reservations did not translated to political opposition.  There was also agreement among 
government officials that material patent is more desirable than just pharmaceutical 
patents since it would also provide incentives to innovate in chemical industries as well. 
The amendment to the patent law to introduce material patents was passed unanimously 
on May 29
, 1975 and became effective from January 1, 1976.     
 
   
   Total  Without  "No  Opinion" 
    In Favor  Against  No Opinion  In Favor  Against 
Total 59.60% 5.60% 31.80%  87.40% 12.60%
Unconditional  6.00%       8.80%   
Chemical 
Material 
Patents  Conditional  53.60%       78.60%   
Total 38.20% 15.90% 45.90%  7.60% 29.40%
Unconditional  5.20%       9.50%   
Pharmaceutical 
Patents 
Conditional  33.00%       61.10%   
   
Table 1: Survey of Japan Patent Association Members (Murayama 1982) 
 
2. Effect on Domestic Pharmaceutical Market 
2.1 Prices 
 
The National Health Insurance (NHI) reimbursement prices are set by the Ministry of 
Health, Labor and Welfare (MHLW). These are the retail prices of drugs in Japan.  A 
price for a drug is determined by a formula that takes into account the size of the market 
as well as the age of the drug.   The price does not reflect what a price usually does: cost 
of production. Since the NHI, and not the consumer, pays for the drug, the price probably 
does not influence the consumption decision.  Thus price not conveying the marginal cost 
of production is not as detrimental to allocative efficiency as when consumption decision 
is based on price.  In case of prescription drugs, the consumption decision is actually 
made by the doctor, which makes price even less relevant for the consumption decision.  
Figure 1 “NHI Reimbursement Prices” shows that the reimbursement prices has been on 











Figure 1: NHI Reimbursement Prices 
 
Real OTC Drug Price Index









Figure 2: Real OTC Drug Price Index 
 
We also note that the price of over the counter drugs have been declining in Japan since 
1970s. (Figure 2 “Real OTC Price Index”).  It actually declined significantly few years before introduction of the product patent.    As we will observe later, number of products 
increased in years following 1076.  This probably contributed to the decline of OTC drug 
prices 
 
Pharmaceuticals contribute to human well-being by preventing and curing diseases, and 
improving over all health.  Did people become healthier because of cheaper drugs?   One 
common measurements of public health is infant mortality, which in Japan has been 
declining steadily.  Life expectancy of people of all ages has been increasing.  One could 
argue that life expectancy of older people, in times of peace, are closely related to 
medical service, particularly pharmaceutical products.      
 
Actually health expenditure has increased in the mean time.  Per capita medical 
expenditure, percentage of medical expense of Gross National Product (GNP) and 
National Income (NI) all have increased.  There is no notable change between 1975 and 
1980, except the rate of annual increase.  (We believe this is due to the large recession 
from the large increase in petroleum in 1973 and 1976, the so called “Oil Shock”.  
Medical expenditure as part of GNP and NI did not change in those years.)  These facts 











Breakdown of Additional Expenses Per Incident
Source: JPMA Facts & Finding 1997 http://www.jpma.or.jp/jpmalib/f_f/f&f-08.html
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Figure 3: Breakdown of Additional Expenses per Incident 
 
The proportion of pharmaceuticals for marginal increase of cost per treatment was little 
under 50% for 1960-65, and has been declining. The proportion for 1970-75 and 1975-80 
did not change significantly at around 25%.  It declined significantly for 1980-85 to 
below 5%.  In the meantime proportion of hospitalization increased.  In 1970-65, it was 
about 10%,  It grew to about 25 % for 197075 and, was about 30% in 1980-85.  (Figure 3: Breakdown of Additional Expenses per Incident.) This shows that controlled drug 
prices did not contribute to the increase in medical costs. 
 
 
2.2 Availability of Drugs 
 
  One concern from introduction of stronger patent protection is that strong 
protection for one product will result in keeping other similar products out of market 
because they now infringe.  This might result in fewer drugs available.  Fortunately this 
did not occur in Japan as the following figures demonstrate.  Figure 4 “Approved 
Pharmaceutical Items” show that although there was a slight drop in number of approved 
drugs in 1978, the number was on an increasing trend for years immediately following 
introduction.  The increase occurred for both domestically produced (includes 
domestically developed and produced under license) and imported.  We can see that 
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Source: JPMA Data Book 1978 
Figure 4: Approved Pharmaceutical Items 
 














Source : The Yakuji Nippo,Recent New Drugs 2004 
Figure 5: Number of Ethical Drug Approvals Granted 
 











Source : The Yakuji Nippo,Recent New Drugs 2004 
Figure 6: Number of OTC Drug Approvals Granted 
 
The increase of products was supported by steady approval of New Chemical Entities 
(NEC).  The number of NECs is far less than number of products and a much larger 
proportion is imported.  Imports increased but they were not driving domestic NECs.  
Strengthening of patent law was thus not driving domestic manufacturers out but helped 
by making the environment more conducive to drug research. 
 











Source: JPMA 2001 "Pharmaceutical Industry of Japan -International Competitiveness Perspective" 
Figure 7: New Chemical Entities 
 
 
2.3 Pharmaceutical Firms  
 
Stronger patent protection means some products are found to be infringing, forced to stop 
production.  A stronger IP regime means firms that cannot obtain patents will be forced to 
go out of business.  In fact, the number of firms did declined between 1975and 1980.   
 
There were 330 ethical drug manufacturers, 666  OTC manufacturers, 363 ethical & OTC 
manufacturers (total 1359) in 1975 (Figure 8 “Number of Domestic Manufacturers”).  
The total number dropped slightly in 1980 but the trend is on the increase.  The increase 
can be attributed to increase in number of manufacturers of ethical only and ethical & 
OTC drugs. Number of OTC manufacturers has been declining.  Although there is some 
research required for OTC drug production, ethical drugs require substantially more.  
Even in 1980 when the total number dropped, the number of ethical only manufacturers 
increased.  
Firms that produce only ethical drugs increased but both OTC only and ethical & OTC 
producing firms declined.  A mild reorganization of the industry did in deed take place.  
 
The reorganization seems to have started prior to the actual introduction of product 
patents.  There were notable increases in 3 and 5 firm concentration ratios while the 10 
firm concentration ratio has declined.  The very largest firms increased market share 
while even the large firms (number 6-10) lost market share (Figure 9: Pharmaceutical 















Source: JPMA Data Book 2004 




















Source: JMPA Data Book 1987 
Figure 9: Pharmaceutical Market Concentration 
  
2.4  Foreign Firms 
 
Entry of foreign firms into the Japanese market also occurred after the new patent law.  
The number of foreign firms (foreign capital accounts for more than 50% of 
capitalization) is shown in Figure 10 “Foreign Firms”. There was a surge over 1965-75 
which coincides with the liberalization of foreign investments during 1967-75.  Probably 
this is the reason for the increase rather than the change in patent law.  However we can 
see there was a qualitative change in investment as result of patent law.  Figure 11 “22 
Foreign Firms in Japan” elaborates the functions of 22
1 major “foreign firm” in Japan. A 
subsidiary in Japan can have one or more of three roles: marketing, research, and 
production.  Interestingly, the numbers of research and production facilities are almost 
the same (we do not have the information to judge how many of these are for the same 
firm.  Obviously some overlap.)   We see the increase coincides more with introduction 
of product patents than capital liberalization.  We observe the effect of capital 






















Source: JPMA 2001 "Pharmaceutical Industry of Japan -International Competitiveness Perspective" 




                                                 
1 Upjohn, Serle, Sandoz,Schering-Plough,Smith-Kline-Beecham,Zeneca,Glaxco,Schering,Ciba－
Geigy,Boehringer Ingelheim,Roche,Novo,Bayer,Banyu,Pfeizer,Fujisawa-Astra,Bristol-Myers 

























Source: JPMA 2001 "Pharmaceutical Industry of Japan -International Competitiveness Perspective" 
Figure 11: 22 Foreign Firms in Japan 
 
Foreign firms had marketing facilities even before capital liberalization.  However they 
began to invest in production and research facilities from the 1970s.  Introduction of 
























Source: JPMA Data Book 2002 
 






 3. Innovation 
 
In this section we analyze the effect of product patents on innovation.  In addition to 
looking at levels of R&D expenditure and patent application, we will try to account to 
change in quality of innovation.   
 
 
3.1 R&D Activity 
  
Pharmaceutical industry’s total R&D expenditure was under 200 million yen in 1967 
which was about 3 % of the total sales.  By the year 1980 R&D expenditure was 190 
billion yen, about 5.5 % of total sales.  By 2000, total R&D expenditure had grown to 
746.2 billion yen and, more importantly, it was 8.6% of sales.

































Source: JPMA Data Book 1987 







                                                 


















Source: JPMA Data Book1987 
Figure 14: R&D Expenditure to Sales Ratio 
 
 
   1983 1984 1985
USA  9.2 9.5 10.1
W. Germany  13.3 15.5   
U.K.  13.1 13.7   
Switzerland          
France  12.3 12.3 12.7
Italy  9.6 9.9   
Denmark  10.3 12   
Japan  6.59 6.49 7.04
 
Table 2: International Comparison of R&D Expenditure to Sales Ratio 
 
Although R&D expenditure as proportion of sales increased significantly in late 1970s, 
the proportion was till quite small by international standards (Table 2).   More recent 











(excluding Japan)              Japan             
                             
Company  1998 1999 2000     Company  1997 1998 1999 2000
                        
 Abbott  9.8  9.1 9.8     Takeda  11.9  11.1  8.4 9.3
 A H P   12.3  13 12.7     Sankyo  11.2  12.5  10.9 14.4
 Astra-Zeneca  NA  16 15.8     Yamanouchi  12  17.5  12.6 11.9
 Aventis  NA  15 14.8     Daiichi 13.1  13.9  11.4 12.6
 Bayer  7.1  8.2 7.7     Eisai  16  18.9  15.4 13.7
 Boehringer 
Ingelheim  18.1  16 15.6     Shionogi  12  12.2  6.8 7.1
 Bristol-Myers 
Squibb  8.6  9.1 10.6     Taisho  8.2  8.8  8.4 12.2
 Eli-Lilly  18.8  18 18.6     Fujisawa  15.1  16.8  15.8 17.5
 GlaxoSmithKline  14.6  15 13.9     Chugai  20.1 20.3 20.5 20.3
 Johnson & 
Johnson 9.6  9.5 10       Banyu 10.2  10.6  11.1 11.1
 Merck  6.8  6.3 5.8     Tanabe  11.3  11.1  10.5 10.2
 Novartis  11.8  13 13     Welfide  8.4  9.6  9.7 10.5
 Novo Nordisk  NA  NA  16.3   
 Kyowa Hakko 
Kogyo  6.7 7  6.7 7.5
 Pfizer  16.8  17 15     Ono  13.2  14.6  15.8 17.6
 Pharmacia  NA  17 15.2     Dainippon  9.1  9.3  7.8 7.9
 Roche   13.8  14 13.8     Meiji Seika  5.7  5.8  4.4 4.9
 Sanofi-Synthelabo  NA  17 15.8     Santen  10.9 10.6  11 11.9
 Schering  NA  NA  18.1     Kaken  8.1  6.7  7.5 7.1
 Schering-Plough  12.5  13 13.6     Tsumura  8.8  8.4  6.3 6.2
 UCB  11.3  12 8.3     Mochida  14.9  13.5  12.9 12.6
Average  12.3  13.2 13.2     Average  11.4  12  10.7 11.3
 
Table 3: R & D Expenditures Proportion of Sales by 20 Leading Pharmaceutical 
Manufacturers (World Wide and Japan) 



















Proportion of R&D Employeer
 
Source: JPMA Data Book 1987 




As shown in Figure 15, in 1975, the earliest for which numbers are available, 12.9% of 
employees at a pharmaceutical company was devoted R&D, on the average for the 
industry.  The number did not change very much until 1979 when there was a noticeable 
increase.  The proportion of R&D employees continued to increase thereafter.   There are 
no international compatible numbers for 1975 but in 1996 the industry average for U.S. 
was 29% for production and engineering and 25% for R&D.   We suspect that in the 
1970s Japanese pharmaceutical companies specialized in manufacturing and had R&D 
capability (14.1 % of employees in 1975) but that was below the level of international 
pioneering firms.    
 
As shown in Table 4, in the decade 1960-70 Japanese firms introduced only 2 new 
products, the number was 4 during 1970-1980.  The number of new products jumped to 
18 in 1980-1990 and was 14 in 1990-2000.   This suggests that Japanese firms began to 




 Table 4: New Product Introduction by Decade 
 
Decade of Introduction  Entity Name  Product Name 
1960-70  Ｓｕｃｒａｌｆａｔｅ    
   Ｍｉｔｏｍｙｃｉｎ  Ｃ    
1970-1980  Ｅｓｔａｚｏｌａｍ    
  Ｄｉｌｔｉａｚｅｍ  hydrochloride    
  Cefazolin  sodium    
   Ｊｏｓａｍｙｃｉｎ    
1980-90  Ｐｒａｖａｓｔａｔｉｎ  sodium  Ｍｅｖａｌｏｔｉｎ 
  Ｃｅｆｐｏｄｏxｉｍｅ  proxetil    
  Surfactant    
  Cefixime    
  Formoterol fumarate    
  Leuprorelin  acetate  Ｌｕｐｒｏｎ 
  Ｅｎｏｘａｃｉｎ    
  Ｆａｍｏｔｉｄｉｎｅ  Ｇａｓｔｅｒ 
 Ｏ ｆ ｌ ｏ ｘ ａ ｃ ｉ ｎ      
  Ａｌｐｒｏｓｔａｄｉｌ  ａｌｆａｄｅｘ  Ｐｒｏｓｔａｎｄｉｎ 
  Ｎｉｃｏｒａｎｄｉｌ    
 Ｃ ｅ ｆ ｏ ｔ ｅ ｔ ａ ｎ      
  Ｎｏｒｆｌｏｘａｃｉｎ    
  Ｃｅｆｔｉｚｏｘｉｍｅ  sodium    
  Ｎｉｃａｒｄｉｐｉｎｅ  hydrochloride    
  Cefoperazone  sodium    
  Latamoxef  sodium    
   Piperacillin  sodium    
1990-2000  Pioglitazon  hydrochloride  Ａｃｔｏｓ 
  Candesartan  cilexetil  Ｂｌｏｐｒｅｓｓ 
  Ｄｏｎｅｐｅｚｉｌ  hydrochloride  Ａｒｉｃｅｐｔ 
  Ｓｏｄiuｍ  Ｒａｂｅｐｒａｚｏｌｅ  Ｐａｒｉｅｔ 
  Ｍｅｒｏｐｅｎｅｍ  tｒｉhydrate    
  Ｉｍｉｄａｐｒｉｌ  hydrochloride    
  Ｔａｍｕｓｌｏｓｉｎ  hydrochloride  Ｈａｒｎａｌ 
  Ｔａｃｒｏｌｉｍｕｓ  hydrate  Ｐｒｏｇｒａｆ 
 Ｓ ｐ ａ ｒ ｆ ｌ ｏ ｘ ａ ｃ ｉ ｎ      
  Ｌｅｖｏｆｌｏｘａｃｉｎ  Ｃｒａｖｉｔ 
  Ｃｅｆｔｉｂｕｔｅｎ    
  Ｌｅｎｏｇｒａｓｔｉｍ    
  Ｌａｎｓｏｐｒａｚｏｌｅ  Ｔａｋｅｐｒｏｎ 
  Ｃｌａｒｉｔｈｒｏｍｙｃｉｎ  Ｃｌａｒｉｔｈ 
 
  
3.2 Patenting Behavior 
 
First we note that immediately following the introduction of product patents, new 
applications were made and number of process patent applications declined (see Figure 
16).  Product patent applications are broken down into pharmaceutical compositions and 































Source: Murayama 1982 
 




Number of patent applications declined for the year the new law came into effect.  But 
this deficit was made up in the following year.  Application for product patents steadily 
increased in numbers and also as proportion of patents in pharmaceutical field.   
 
One suspects that this is an indication of change in type of innovation that firms engaged 
in.   Firms concentrated on developing new methods of making existing drugs before 
1976.   When it became possible to patent product or material patents, firms began to 
concentrate on developing new compounds and substances.   













Source: JPMA Data Book 1987 
Figure 147: Pharmaceutical Patent Application (in Japan) 
 
 
Number of pharmaceutical patents in Japan has continued to increase, although the 
increase is small compared to Germany and U.S.A. (Figure 18).  The proportion of 
pharmaceutical patents among all patents is small compared to other countries and the 
trend is to decline (Figure 19).  This could reflect decline in productivity of the 
pharmaceutical industry, other industries are more productive, or size the pharmaceutical 
industry has declined relative to the whole economy.  Because number of pharmaceutical 
patents has not declined (Figure 17), the last two explanations are more likely.  It could 
be that electronic industries are particularly productive.   
 






















Source: JPMA Databook 2003, Databook 1987 
 


























Source: JPMA Databook 2003, Databook 1987 
 
Figure 19: Proportion of Pharmaceutical Patents in Total Patents in U.S.A., 
Germany and Japan  
3.3 Quality of Innovation 
 
Both levels of R&D and patenting have risen but not so significantly.  This was the case 
when patent scope was enlarged in 1988 (Sakakibara and Branstetter (2001).  Okada and 
Kawara (2002) have provided evidence based on US patent citations that Japanese firms 
indeed became innovative as result of introduction of the product patent.  One measure of 
innovativeness of a new patent is how often that patent is cited in applications of later 
patents, i.e., number of forward citations.  Between 1975 and 1980, number of Japanese 
patents (patents registered by Japanese firms in the U.S.) cited by more than 10 patents 
doubled while the number remained steady over those year for U.S. originating patents 
(U.S. patents registered by U.S. firms).  This implies there was definitely a significant 
improvement in quality of research output by Japanese firms and this was not based on 
some underlying scientific breakthrough available internationally.   
 
We have observed that proportion of R&D workers has also increased.  Most importantly, 
that firms indeed switched from process to product patenting.  This seems to imply a 
change in quality or direction of pharmaceutical innovation.  We could interpret the 
change as from modification to application innovation as classified by Hara (2003).  
Probably the modification should include process modification.   Both switch from 
process modification to product modification and from modification to application would 
be consistent with Table 2 “New Product Introduction by Decade”.   Either interpretation 
is consistent with increase in the inventive step from introduction of product patents.        
 
3.4 Individual Firms 
 
Figures 13 and 14 demonstrated that that R&D expenditure itself and its ratio to total 
sales both increased significantly after 1975.
3  What is suggested by the macro data is 
supported by evidence of several firms (all one of the top 10 firms in terms of 
capitalization in fiscal year 2003).  Although there is no increase in case of Firm A, other 
firms show increase in both R&D expenditure as percentage of sales and R&D 
employees as percentage of total employees.  (These percentages increases could be due 
to decrease in the denominators, but both total sales and total number of employees 
increased for all firms during the period.)     
 
There is a significant increase of foreign patenting by Firms A, B and E.  There is 
increase in R&D effort by Firms B and E and but not by Firm A. there was no noticeable 
increase in R&D effort but a significant increase in number of patent application abroad. 
Firms C and D has increase in R&D effort but there seems to be no significant change in 
patenting behavior.  
 
In interpreting these numbers, it is important to remember the two changes: publication of 
patent applications and examination request system, introduced in 1970.   Publication 
makes patent applications more risky (Aoki and Spiegel 1998).  This might have worked 
                                                 
3 Many of our data begin from 1975.  We looked for date prior to 1975, but interestingly many of the data 
for the industry starts from 1975.  against the incentive to patent more after the products became patentable.  Need to 
request examination also increased the cost of patent application. 
 
(Figures 20- 29 were constructed by data provided by individual firms to the Japan 
























Figure 20: Firm A R&D Expenditure & Employee 
 













































































































































































































































Figure 26: Firm D R&D Expenditure and Employees 
 
 

























































Figure 28: Firm E R&D Expenditure and Employees 
 
 













































































4. Relationship to International Market 
 
4.1 Foreign Markets 
 
There is evidence that Japanese firms are producing products that are competitive on the 
international market.  In 1972 there were no Japanese firms in the top 20 firms according 
to sales.  In 2002, there was one (Takeda) in the top 20 at number 15.  Japanese firms also 
occupied 21-23
rd places.  This fact has often been cited as evidence of Japanese 
pharmaceutical firms becoming more competitive.  In this section, we look at the matter 
for years immediately following introduction and in more detail. 
 
Growth in sales could be attributed simply to expansion of the size of the Japanese 
domestic market relative to the international market.  But the growth in sales seems to be 
from greater penetration of the international market (Figure 31 “Foreign Businesses of 
Japanese Firms”. The numbers include pharmaceutical raw materials, medical devices 
and tools, food supplements businesses and research facilities.).  In 1975 there were only 
30 foreign subsidiaries of more than 50% ownership.  In 1995, there were 146 such 
subsidiaries.   
 
 




















Source: Yano Research Institute (JPMA Website) 











1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985
New drugs
New drugs sold abroad
 
Source: JPMA Data Book 1987 
Figure 32: New Product Introductions 
 
 4.2 Technology Trade 
 
Revenue in Figures 33-37 refers to revenue from technology exports and expenditure is 
payment for imports.  Both values of imports and exports were on an increasing trend, 
but always in deficit until 1984.  The following figures show import and export of 
pharmaceutical technologies.  We refer to them as “licenses” although they are not 
restricted to production under licenses.  Selling production know-how would be included 
in technology trade.  
 












Source: JPMA Data Book 1987 
Figure 33: Pharmaceutical Technology Trade (Value 10 Mil yen) 
 
 
Technology trade in terms of value was in deficit for years after product patent 
introduction.  Number of licenses (as noted before, not only production under license but 
includes other technology transfers), were more balanced.  This means the imported 
technologies are on the average more valuable than exported technologies.  The change in 
balance of trade in value changed because the new technologies exported were 
significantly more valuable than those imported.  The balance of trade of new 
technologies narrowed and became balanced after the introduction of product patents.  
Both number and values of new exports is greater than new imports.  The average value 
of newly exported licenses is significantly larger than those imported.  This suggests that 
the Japanese technology level (value) lagged those of the world market prior to 















Source: JPMA Data Book 1987 
Figure 34: Pharmaceutical Technology Trade (Number of Licenses) 
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Figure 197: Value per New License While increasing technology exports, Japanese firms have also made direct foreign 
investments abroad. (Figure 38).  We see that there was a significant increase of 
marketing and production facilities in late 1970s and in 1980s.   This could mean that 
Japan started to develop products that were more competitive on the international market, 
making such investments worthwhile. 
 
 















Source: JPMA Data Book 1987 
Figure 208: Foreign Subsidiaries of Japanese Firms 

















Source: JPMA Data Book 1987 
Figure 39: International Comparison of New Drug Introductions  


































































Source: JPMA Data Book 1987 
Figure 40: Where Drugs were Developed 
 
Figure 39 “International Comparison of New Drug Introductions” shows that Japan’s 
introduction of new drugs increased slightly after introduction of new drugs.  From a 
country with relatively few new introductions, it became more comparable with other 
nations after the introduction.  Interestingly, the number of new drug introductions in 
different countries converged in the 1980s.  Notice the number in West Germany was 
much larger than other countries in 1975, the number dropped and has converged to be 
level similar with other countries.  
 
Figure 40 “Where Drugs were Developed” shows that 25% of drugs available in Japan 
were developed in Japan.  This is a very high domestic origin with exception of USA and 
France.  While the number of drugs of U.S. origin that are available in U.S. itself is 
similar or less than what is available in other countries, number of drugs developed in 
Japan and available elsewhere is very small.  Japan (as well as France) has a 









 5. Analysis and Conclusion 
  
Intellectual property achieves dynamic efficient allocation of scare resources by 
introducing a short run inefficiency into the economy.  The short run dead weight loss 
can be tolerated only if there are benefits in the long run.  Introduction of product patents 
strengthens protection and changes the balance of short run loss and long run benefit.  
However there is a slight difference between introducing new protection and simply 
strengthening existing technology protection such as widening breadth.  When patent 
protection is simply strengthened, newer technologies must overcome a greater inventive 
step to be patentable.  In case of introduction of product patents, new processes are still 
protected, with the same level of inventive step.    Thus there is short run loss from 
forgone introduction of new products but the legal opportunities for cost reduction have 
not been compromised.   This difference is important in understanding the data.    
 
In case of Japan, retail prices are set by the MHLW and are independent of market 
structure.  Thus consumers do not immediately lose from stronger protection.  Firm profit 
is determined by the wholesale market and the introduction of product patents could have 
restricted competition in the wholesale market in the short run.  But there is no evidence 
of decline in availability of products.   We observed the availability of OTC was not 
affected (and prices have been on a decline) after the introduction of patent laws.  This 
could be because marginal productivity of product innovation was sufficiently high so 
that long run benefit of protection was realized very quickly.  There was however a mild 
reorganization of the industry.  Concentration at the very top increased, but concentration 
of top 10 firms declined.   The increase in concentration may be the result of higher entry 
barrier due to greater inventive step of patentability.  Also, because technological 
opportunities for cost reduction had been declining for existing drugs, it could have been 
only the largest firms that could continue to make use of the process patent.   
 
One notable pro-competitive phenomenon is that entry of foreign firms into Japan 
increased after the introduction.  This was aided by capital liberalization which started 
before the patent law change.  We infer that increase of research facilities was motivated 
by the new law.  Foreign firms contributed to competition in the short run but also helped 
increase the number of new products available in Japan in the long run.   
 
In considering the long run benefit, we again need to take into account the fact that 
introduction of product patents is different from simple strengthening.   The long run 
benefit may not just be an increase in R&D activity.  In fact we observed a qualitative 
change in R&D.  After the introduction of the law, number of process patents decreased 
significantly but the total number of pharmaceutical patents increased slightly due to the 
new product patents.  Firms increased both the absolute number of R&D expenditure and 
as proportion of sales increased around 1976 and continued to increase.  Firms also 
increased the proportion of research employees.   
 
These changes lead us to conclude that quality or type of pharmaceutical innovation 
changed as result of introduction of the law.  This resulted in change in quality of 
innovation: from process to product and modification to application.   As the law was intended, firms reallocated resources from finding new ways of producing an existing 
drug to finding new products.  This qualitative change is also reflected in the shift if the 
trading pattern of pharmaceutical technologies.  The quality became more in line with the 
imported technologies suggesting Japan caught up.   
 
The change in innovation output was achieved by a change in the innovation regime from 
basic to applied research.  The long run benefit of such changes would take decades to 
materialize.   Japan continues to increase foreign direct investments for marketing and 
production of products developed in Japan.  Both number of Japanese subsidiaries abroad 
and foreign subsidiaries in Japan increased.  However both shares are small suggesting 
the Japanese market continues to be somewhat separated from the rest of the world.  
 
Implications to Developing Countries 
 
The Japanese experience shows that the analyses of pharmaceuticals as part of health 
policy and pharmaceuticals as part of technology or industrial policy need to be separated.  
In case of Japan, merits of product patents were not debated as part of health policy.  This 
may be due to the fact that prices are regulated and other medical services readily 
available.  Alternative to a drug at a particular price is not only the same drug at another 
price, but a similar drug or a different medical treatment.   It is true that drugs that can be 
administered with minimum professional advice are probably very cost effective and 
should be considered essential.  But perhaps this is not the case for all drugs.  
 
Japan focused on the benefits of product patents form industry policy point.  It was felt 
that the benefit from protecting only process innovations had been exhausted and there 
was a need for change of direction.  It is important to note that debate was actually on 
changing the nature of protection and not simply strengthening.  And the data show that 
implication was just that.  There was some short run inefficiency from introducing new 
protection, as expected.   
 
In the current debate in developed countries, it is important to separate the industrial 
policy from the public health debate.  In countries such as India where a certain level of 
technology has been achieved, this aspect is very important as was in Japan in the 1970s.  
And it is important to note that the long run benefit may not only be from more 
innovation but a change in quality of innovation.  It may be that most technological 
opportunities that are meaningful under current scope of protection have already been 
exhausted.   More productive and internationally competitive industry will benefit a 
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